OrthAlign Announces Clinical Milestone Having Performed 200,000 Joint Arthroplasty Cases Worldwide

OrthAlign, Inc., a privately held U.S.-based medical device and technology company providing orthopedic surgeons with advanced precision technologies, announced a clinical milestone of 200,000 OrthAlign-assisted joint replacement surgeries worldwide.

Indicated for total knee replacement, partial knee replacement, and total hip replacement, OrthAlign’s intuitive, handheld navigation technologies provide an accurate, cost-effective tool ideal for both the hospital and ASC environments.

OrthAlign delivers accurate, individualized alignment to any patient with a single-use, handheld smart tool that can be used across implant platforms and surgical philosophies. The user-friendly design and interface provide streamlined workflows to reduce OR times and support multiple ORs concurrently without the investment, equipment, or pre-operative imaging required by many computer-assisted surgical systems. The technology is optimized for the ASC with only one instrument tray, one navigation unit for all applications, and no storage requirements or service plans.

A steady cadence of updates and product launches have supported the exponential adoption and growth of OrthAlign technology. KneeAlign®, the company’s flagship application, provides tibial and femoral intra-operative navigation for total knee arthroplasty. UniAlign®, launched in early 2017, leveraged the clinical success of KneeAlign, and allows for a seamless transition between partial and total knee replacement. In 2018, HipAlign® became commercially available and currently supports real time abduction and anteversion measurements of the acetabular cup and assess intra-operative changes in leg length and offset for both lateral or supine based approaches.

“OrthAlign has given me accuracy and reproducibility,” said Dr. Rafael Sierra, Orthopedic Surgeon in Rochester, MN. “My first introduction to OrthAlign was a tough case with hardware in the femur, and I wanted to see if I could avoid taking the hardware out of a young patient. OrthAlign was the perfect instrument for that situation. After that experience, I was very excited about its use and expanded it into my other knee replacements. When performing anatomic alignment, it is very challenging, with manual instrumentation, to determine the exact degree of a slightly varus tibial cut. You want consistent precision, and that’s what OrthAlign gives me.”

“This is another great milestone for our organization that emphasizes the commitment of surgeons to our products,” said Eric Timko, Chairman and CEO of OrthAlign Inc. “This has been an exciting journey for OrthAlign and with the launch underway of our next generation flagship product, Lantern, we expect our strong momentum to continue. Technology in every room and in every case is the future; OrthAlign is the catalyst to make that happen. We’ve seen market-leading growth, quarter after quarter, because our surgeons love the simplicity and efficiency of the system, and they’re seeing great results. As the market continues to adopt technology and total joints move to the ASC, we are well positioned to drive these transitions and deliver clinically-proven technology that meets the operational and financial needs of all sites of service. Our future is bright, and we look forward to what’s ahead.”

Hot this week

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”

Avery Dennison Medical Introduces Ipdated SilFoam Lite: Sustainability, MDR Certification & Performance Improvements

The newly enhanced SilFoam Lite delivers superior efficiency and reliability, bringing improved fluid handling capabilities and improved tack. These improvements make the product ideal for customers seeking quality, high-performance solutions in wound care notes Avery Dennison Medical.

Voluntary Recall Notifying Medtronic Insulin Pump Users of Potential Risks of Shortened Pump Battery Life

Medtronic plc voluntarily issued a field action starting on July 31, 2024, notifying global customers of its MiniMed™ 600 series or 700 series insulin pumps to follow their pump's built-in alerts and alarms for battery status and to contact Medtronic if they observe changes in the battery life of their pump

Medtronic Expands AiBLE Spine Surgery Ecosystem with New Technologies and Siemens Healthineers Partnership

New advancements in the AiBLE Spine Surgery ecosystem build upon the company's commitment to procedural innovation and execution